Topic Code
HORIZON-HLTH-2026-04-CARE-04
F&T Portal
Call Identifier
HORIZON-HLTH-2026-04
Partnerships in Health (2026/3)
Instrument
HORIZON-COFUND
Programme Co-fund Action
Budget Model
Actual Costs
30% funding rate
Funding Rate
30%
COFUND — max 30% of eligible
Page Limit (Part B)
65 pages
COFUND (Annex A)
Evaluation Thresholds
4 / 4 / 4 · cum. 12
Non-standard — topic override
Expected Projects
1
Partnership top-up (WP stated)
Destination
Ensuring equal access to innovative, sustainable, and high-quality healthcare
WP Part 4
Cluster / Pillar
Cluster 1 / Pillar II
Health
China Eligibility
Eligible ✓
COFUND not restricted (RIA/IA only)
Special Conditions
Existing partnership only ⚠
Must be current EP PerMEd coordinator
Restricted to existing partnership coordinator. The proposal must be submitted by the coordinator of the consortium funded under HORIZON-HLTH-2023-CARE-08-01 (European Partnership on Personalised Medicine).
This topic uses non-standard evaluation thresholds: 4 (Excellence) / 4 (Impact) / 4 (Implementation), cumulative 12. Standard thresholds are 3/3/3 cumulative 10.
US entities eligible: In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, legal entities established in the United States of America are eligible to receive Union funding under this topic.
Copernicus/Galileo: If the project uses satellite-based earth observation, positioning, navigation and/or related timing data, beneficiaries must make use of Copernicus and/or Galileo/EGNOS.
Expected Outcomes
- European countries and regions, along with international partners, are engaged in enhanced collaborative research efforts for the development of innovative personalised medicine approaches regarding prevention, diagnosis and treatment.
- Healthcare authorities, policymakers and other stakeholders develop evidence-based strategies and policies for the uptake of personalised medicine in national or regional healthcare systems.
- Health industries, policymakers and other stakeholders have access to efficient measures and investments to allow swift transfer of research and innovation into market.
- Health industries and other stakeholders can accelerate the uptake of personalised medicine through the adoption of innovative business models.
- Healthcare authorities, policymakers and other stakeholders use improved knowledge and understanding of the health and costs benefits of personalised medicine to optimise healthcare and make healthcare systems more sustainable.
- Healthcare providers and professionals improve health outcomes, prevent diseases and maintain population health through the implementation of personalised medicine.
- Stronger and highly connected local/regional ecosystems of stakeholders, including innovators, are in place and facilitate the uptake of successful innovations in personalised medicine, thus improving healthcare outcomes and strengthening European competitiveness.
- Citizens, patients and healthcare professionals have a better knowledge of personalised medicine and are better involved in its implementation.
- Stakeholders cooperate better and establish a network of national and regional knowledge hubs for personalised medicine.
Want the full analysis?
The key facts above tell you WHAT. The full Decision Brief tells you HOW to win.
Compliance traps
Scoring playbook
Consortium blueprint
Positioning guide
Red flags
Quick-start checklist
Order Full Brief — €79
Delivered within 1 working day
Disclaimer: This page is produced using advanced AI analysis and reviewed by an experienced EU grant engineer. While we take care to ensure accuracy, the information may contain errors or become outdated. It is the applicant’s sole responsibility to verify all facts against the official
EU Funding & Tenders Portal before making any decisions. Global Disruption accepts no liability for errors, omissions, or decisions made based on this content. No refunds are offered for Key Facts pages or Decision Briefs.